Advertisement
Organisation › Details
Khloris Biosciences Inc.
Khloris Biosciences is a biotechnology startup founded in 2017 developing a novel approach for anti-cancer vaccines using induced pluripotent stem cells (iPSCs) to trigger a robust immune-response involving innate and adaptive immune cells. The company is located in South San Francisco, California. Khloris is a spinout of the technology that was developed in the laboratory of Prof. Joseph C. Wu , Director of the Stanford Cardiovascular Institute and Professor in the Department of Medicine and Department of Radiology at the Stanford University School of Medicine. Lynne A. Bui, MD is the co-founder and CEO of Khloris, founder and Chairman of Global Cancer Research Institute (GCRI), and has broad experience in hematology/oncology R&D throughout the industry and academia. *
Start | 2017-01-01 established | |
Predecessor | Stanford University School of Medicine | |
Industry | iPSC technology (induced pluripotent stem cell technology) | |
Industry 2 | cancer vaccine | |
Person | Bui, Lynne A. (Khloris Biosciences 201904 CEO + Co-Founder) | |
Region | South San Francisco, CA | |
Country | United States (USA) | |
Street | 329 Oyster Point Blvd. | |
City | 94080 South San Francisco, CA | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Bayer AG. (4/2/19). "Press Release: Leaps by Bayer and Khloris Join Forces to Develop Induced Pluripotent Stem Cells (iPSCs) as Breakthrough Anti-cancer Vaccines". Leverkusen & South San Francisco, CA. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Khloris Biosciences Inc.
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top